Brought to you by 
Valeant gets Elidel and Xerese rights in the US, Canada, and Mexico from Meda
16 Nov 2015
Executive Summary
The same day specialty pharma Meda AB acquired global rights to Elidel (pimecrolimus) cream 1% from Novartis AG for $420mm, Meda made a commitment in principle to out-license US, Canadian, and Mexican rights to the drug to Valeant Pharmaceuticals International Inc. (skin and neurology drugs). Elidel has been approved for mild-to-moderate atopic dermatitis.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Valeant gets Elidel and Xerese rights in the US, Canada, and Mexico from Meda
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice